Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Debt (2016 - 2025)

Historic Total Debt for Avalo Therapeutics (AVTX) over the last 11 years, with Q2 2025 value amounting to $370000.0.

  • Avalo Therapeutics' Total Debt changed N/A to $370000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $370000.0, marking a year-over-year change of. This contributed to the annual value of $360000.0 for FY2024, which is N/A changed from last year.
  • Avalo Therapeutics' Total Debt amounted to $370000.0 in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Total Debt ranged from a high of $32.8 million in Q4 2021 and a low of $360000.0 during Q4 2024
  • For the 5-year period, Avalo Therapeutics' Total Debt averaged around $11.6 million, with its median value being $12.0 million (2022).
  • Data for Avalo Therapeutics' Total Debt shows a peak YoY increase of 5892.55% (in 2022) and a maximum YoY decrease of 5892.55% (in 2022) over the last 5 years.
  • Avalo Therapeutics' Total Debt (Quarter) stood at $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then decreased by 22.36% to $10.5 million in 2023, then tumbled by 96.56% to $360000.0 in 2024, then increased by 2.78% to $370000.0 in 2025.
  • Its Total Debt stands at $370000.0 for Q2 2025, versus $360000.0 for Q1 2025 and $360000.0 for Q4 2024.